Table 1

Summary of clinical trials

StudyRA populationStudy location(s)Time point analysesTreatment arms (n) identifierPrimary publication
PRESERVE (N=826)ModerateGlobal: Asia, Australia, Europe, Latin AmericaWeek 36ETN plus MTX (826)*NCT00565409Smolen et al19
COMET (N=528)Early, moderate-to-severeGlobal: Asia, Australia, Europe, North America, Scandinavia, South America, Middle EastWeek 52ETN plus MTX (265)†;
MTX (263)
NCT00195494Emery et al16
TEMPO (N=459)Established, moderate-to-severeGlobal: Australia, Europe, Middle East, ScandinaviaWeek 52ETN plus MTX (231)†;
MTX (228)
NCT00393471Klareskog et al17
APPEAL (N=300)Established, moderate-to-severeAsia-PacificWeek 16ETN plus MTX (197)‡;
NCT00422227Kim et al9
LARA (N=421)Established, moderate-to-severeLatin AmericaWeek 24ETN plus MTX (279)†;
DMARD plus MTX (142)
NCT00848354Machado et al18
  • N (or n) represents the number of patients at final time point in this analysis.

  • *Open-label ETN 50 mg+MTX only.

  • †ETN 50 mg weekly plus MTX.

  • ‡ETN 25 mg twice weekly (equivalent to ETN 50 mg weekly) plus MTX.

  • DMARD, disease-modifying antirheumatic drugs; ETN, etanercept; MTX, methotrexate; RA, rheumatoid arthritis.